Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2024-12-11
2024-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eye Cream 8-Week Efficacy Clinical Study
NCT07079501
ANTI-DYNAMIC LINE Test for Cream
NCT07067073
12-Week Study on the Efficacy of Two Serums in Improving Skin Aging and Tone
NCT07156071
Lotion and Toner Bundle 4-Week Lifting Efficacy Study
NCT07127653
Test Serum Clinical Study
NCT07200635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Cream Single Application Group
Participants applied the test cream (Formula# 899675 44A, 30 mL) once to the full face and neck under staff supervision. Application was followed by massaging designated wrinkle-prone areas including the forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical assessments and imaging analysis were performed at T0, T10h, and T24h post-application.
Test Cream
A facial cream (Formula# 899675 44A, 30 mL) was applied once by participants under supervision. 1g of cream was spread over the entire face and neck, followed by targeted massage on wrinkle-prone areas including forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical and photo-based evaluations were conducted at baseline (T0), 10 hours (T10h), and 24 hours (T24h) after application.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test Cream
A facial cream (Formula# 899675 44A, 30 mL) was applied once by participants under supervision. 1g of cream was spread over the entire face and neck, followed by targeted massage on wrinkle-prone areas including forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical and photo-based evaluations were conducted at baseline (T0), 10 hours (T10h), and 24 hours (T24h) after application.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
8.Did not participate any chemical/beauty procedures for previous 6 months. 9.No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
10.Were willing and able to participate as evidenced by signing of informed consent and photo release form.
11.Must be willing to comply with all study protocol requirements.
Exclusion Criteria
2.Subject deprived of rights by a court or administrative order. 3.Major subject to a guardianship order. 4.Subject residing in a health or social care establishment. 5.Patient in an emergency setting. 6.Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
7.Subject presenting a stable or progressive serious disease (per investigator's assessment).
8.Immuno-compromised subject. 9.Subject with history of allergy to cosmetic or personal care products or ingredients.
10.Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
11.Subjects regularly practicing aquatic or nautical sports. 12.Subjects regularly attending a sauna. 13.Subject with physical highly sensitive constitution. 14.Subject with cardiovascular or circulatory history. 15.Subject with a history of skin cancer or malignant melanoma. 16.Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.
20 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChinaNorm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C24005077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.